



CURRICULUM VITAE



Delaram Doroud, Pharm D., Ph.D

Address:

Production and research complex.

Pasteur Institute of Iran

Tel: 0098 26 36100454

Website:http://scholar.google.com/citations?user=7q007_IAAAAJ&hl=en

<http://en.pasteur.ac.ir/pages.aspx?id=856>

<http://www.pasteur-prc.ir/%D8%B1%D8%A6%DB%8C%D8%B3-%D9%85%D8%AC%D8%AA%D9%85%D8%B9>

E-mail: delaramdoroud@yahoo.com

d_doroud@pasteur.ac.ir

Category of research:

-) Nanobiotechnology
-) Quality aspects of the Pharmaceutical and Diagnostic Productions
-) Drug/Vaccine delivery systems and Adjuvants
-) Human vaccine production
-) Leishmaniasis

Current Research Interests:

- 1- Quality Management Systems (Quality control, Quality assurance, Risk assessment)
- 2-Development of Vaccine and Drug Delivery Systems
- 3- Development of new vaccine against cutaneous leishmaniasis using new drug delivery systems such as solid lipid nanoparticles as immunoadjuvant with recombinant Antigens rCPs).

4- Developments of topical SLN's containing different anti-leishmanial drugs such as paromomycin for the treatment of coetaneous leishmaniasis.

5- Development of lipid based nanoparticles for nucleic acid delivery.

Education:

-) 2006-2011: PhD Student of Pharmaceutical Sciences, Faculty of Pharmacy, Tehran University of Medical Sciences. Thesis: Preparation and Evaluation of solid lipid nanoparticle-*cystein* *proteinase* gene vector as a *Leishmania* vaccine novel formulation, Supervisors : Prof. Sima Rafati, Dr. Rouholamini Najafabadi and Dr. Alireza Vatanara

-) 1994- 1998 Pharmacy, Azad University, Tehran , Iran. THESIS: Synthesis and Evaluation of the Anticuvulsant Effects of New GABA Prodrugs. Supervised By: Dr. Ali Khalaj and Dr. Mohammad Hussein Pourgholami

Skills

-) Certificate with final qualification of “Excellent” from The center for Genetic and Biotechnology and Heber Biotec S.A., September, 2005 for GMP requirements.

-) Certificate with final qualification of “Excellent” from The center for Genetic and Biotechnology and Heber Biotec S.A., September, 2005 for Documentation course.

-) Certificate with final qualification of “Excellent” from The center for Genetic and Biotechnology and Heber Biotec S.A., September, 2005 for Batch Release course.

Positions:

-) March 2018-Present, Member of the board directorates, Pasteur Institute of Iran.

-) March 2018-Present, Production Directorate and the head of production and research center, Pasteur Institute of Iran.

-) March 2018-Present, head of biotechnology incubator center of Pasteur Institute of Iran.

-) March 2018-Present, head of biotechnology Park center of Pasteur Institute of Iran.

-) August 2016- March 2018, Quality Manager and Authorized person. Pasteur Institute of Iran.

-) October 2014-present, Authorized Person and Head of Regulatory Department, Pasteur Institute of Iran.

-) January 2013- October 2014, Head of Quality Assurance Department, Pasteur Institute of Iran.

-) Aug 2011- June 2013, Head of Quality Control Department, Pasteur Institute of Iran

-) May 2011-Aug 2011, Recombinant Products Production Quality Supervisor, Pasteur Institute of Iran.

-) 2006-present, PhD student at molecular immunology and vaccine research laboratory, Pasteur Institute of Iran

-) 2005-2008, Head of Documentation and Batch Release Dep. in Quality Assurance Department, Pasteur Institute of Iran

-) 2000-2005, Researcher, Biotechnology Department, Pasteur Institute of Iran

International and national Grant Support:

1. Deglycosylation possibility investigation of recombinant human alpha erythropoietin during downstream process
2. In vitro evaluation of solid lipid Nanoparticle harboring paramomycin on Leishmania major
3. Design and construction of a vector for recombinant protein expression in the yeast Hansenula polymorpha and expression of Granulocyte colony stimulating factor (GCSF) as a candidate protein
4. Preparation and evaluation of different therapeutic tools using alpha defensin (HNPI) and IP-10 in infected L. major Balb/c mice
5. Preparation of primary roadmap for national oncolytic virus research
6. Evaluation, comparison and update of pharmacopeial specifications of 4 recombinant products in the past 15 years in order to increase of their quality and safety
7. Comparison of the Different Production methods and Evaluation of the Surface Modified Fluorescent Labeled Solid lipid Nanoparticles Loaded by rHBsAg as a Novel Adjuvant and Vaccine Delivery System
8. Evaluation of physic-chemical and biological (potency) characteristics of conjugated and nonconjugated chitosan nanoparticles loaded with recombinant hepatitis B Surface antigen (rHBsAg) as the vaccine delivery system and adjuvant

9. Scale up, development and validation of a bioreactor based parasite using *Leishmania (L.) tarentolae* secreting PpSP15 as vaccine candidate
10. Formulation and Stability Studies of the Recombinant Erythropoietin alpha in Citrate Sodium Buffer
11. recombinant Human Bone Morphogenetic Protein-2 in CHO-S Cell Line
12. Design of ELISA kit for quantitative analysis of HBsAg
13. screening of critical parameters for purification of hepatitis B surface antigen using multimodal matrices: Evaluation of yield, purity, multimeric forms and potency
14. Determination of influential parameters for predicting efficiency of endotoxin removal processes from recombinant therapeutic proteins and establishing the related statistical model
15. Validation of Monocyte Activation Test kit for detection of pyrogens in recombinant Hepatitis B vaccine and comparison with RPT
16. Preparation of antibody against human IgG and comparison with commercial anti human globulin in Coombs Wright test
17. Immunologic evaluation of recombinant protein HAV-VP1 in BALB/c mouse as a vaccine candidate
18. Cloning and expression of interferon alpha 2b mutant protein suitable for specific PEGylation, in *Escherichia Coli*
19. PCR-RFLP analysis of conserved and non-conserved genes of *Helicobacter pylori* strains isolated from Iranian dyspeptic patients. Funded by: **Societe de Pathologie Exotique, Paris, France. 2000**
20. Evaluation of antibiotic resistance in *Helicobacter pylori* via molecular assays. Funded by: **Pasteur Institute of Iran, Tehran, Iran. 2003**

PUBLICATIONS: (Start from most recent)

- 1- HediyeH Rassam, Abdolamir Allameh, Akram Eidi, Mahmoud Alebouyeh, Delaram Doroud *, Novel Formulation for Recombinant Streptokinase by. Solid Lipid Nanoparticle: A Light at the End of the Tunnel, Arch Pharma Pract 2020;11(S1):149-55-.
- 2- HediyeH Rassam, Abdolamir Allameh, Akram Eidi, Mahmoud Alebouyeh, Delaram Doroud *, : Streptokinase Loaded Solid Lipid Nanoparticles: Preparation and characterization Archives of Pharmacy Practice | Volume 10 | Issue 4 , 2019

- 3- Mohsen Mehrabi, Shima Sadeghi-Soureh, Naser Mohammadpour Dounighi, Seyed Mahdi Rezayat, **Delaram Doroud**, Mehdi Khoobi, Amir Amani Development and optimization of hepatitis B recombinant antigen (rHBsAg) loaded chitosan nanoparticles as an adjuvant by a design of experiment approach *Micro & Nano Letters*
- 4- NV Barzi, Z Eftekhari, **D Doroud**, A Eidi. [DNA methylation changes of apoptotic genes in organogenesis stage of mice embryos by maternal chlorpyrifos induction](#), *Environmental Toxicology* 35 (7), 794-803, 2020
- 5- P Gheibi, Z Eftekhari, **D Doroud**, K Parivar, [Chlorpyrifos effects on integrin alpha v and beta 3 in implantation window phase](#), *Environmental Science and Pollution Research*, 1-9, 2020
- 6- A Hajhosseini, **D Doroud**, A Sharifan, Z Eftekhari, [Optimizing Growth Conditions of Kluyveromyces marxianus for Mannan Production as a Bioemulsifier](#), *Applied Food Biotechnology* 7 (2), 115-126, 2020
- 7- M Khosravi, M Rahimi, **D Doroud**, ES Mirsamadi, H Mirjalali, MR Zali, [In vitro Evaluation of Mannosylated Paromomycin-Loaded Solid Lipid Nanoparticles on Acute Toxoplasmosis.](#), *Frontiers in Cellular and Infection Microbiology* 10, 33-33, 2019
- 8- S Maslehat, **D Doroud**, [Pasteur Institute of Iran; a Leading Institute in the Production and Development of Vaccines in Iran](#). *Vaccine Research* 6 (1), 33-42, 2019
- 9- HGJ Leila, M Abolhassani, SN Hosseini, B Ghareyazie, L Ma'mani, **D Doroud** Effects of Electromagnetic Fields Exposure on the Production of Nanosized Magnetosome, Elimination of Free Radicals and Antioxidant Defense Systems in Magnetospirillum. *Journal of Nano Research* 58, 20-31, 2019
- 10- MohsenMehrabi· Naser Mohammadpour Dounighi· Seyed Mahdi Rezayat· **Delaram Doroud**· Novel approach to improve vaccine immunogenicity: Mannosylated chitosan nanoparticles loaded with recombinant hepatitis B antigen as a targeted vaccine delivery system, *Journal of Drug Delivery Science and Technology* 44, 19-26, 2018
- 11- MohsenMehrabi· Naser Mohammadpour Dounighi· Seyed Mahdi Rezayat· **Delaram Doroud**· Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan nanoparticles: as a novel vaccine delivery system and adjuvant, *Artificial cells, nanomedicine, and biotechnology*, 1-11, 2017.
- 12- M Heidari-Kharaji, T Taheri, **D. Doroud**, S Habibzadeh... Enhanced paromomycin efficacy by Solid Lipid Nanoparticle formulation against Leishmania in mice model - *Parasite immunology*, 2016
- 13- M Heidari-Kharaji, T Taheri, **D. Doroud**, S Habibzadeh... Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model - *Applied microbiology and biotechnology*, 2016

- 14- Maryam Heidari Kharaji, **Delaram Doroud**, Tahereh Taheri, Sima Rafati Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against *L. major* and *L. tropica*. *AAPS PharmSciTech* 2015 November 9
- 15- Mehdi Shahbazi, Farnaz Zahedifard, Noushin Saljoughian, **Delaram Doroud**, Shahram Jamshidi, Niousha Mahdavi, Sadegh Shirian, Yahya Daneshbod, Sayyed Hamid Zarkesh-Esfahani, Barbara Papadopoulou, Sima Rafati, Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis, *Veterinary parasitology*, 2015-09-21
- 16- H Mahdiani, **D Doroud**, MH Haghparvar, SN Hoseini, Safety and Immunogenicity of Hepatitis B Vaccine: a Study on Iranian Navy Personnel, *Vaccine Research*. 2015; 1(2), 34-37
- 17- Mahdiani, M; **Doroud, D**; Shahali, M; Pouyan, N; Brufar, F; Rahimi, A; Vaez, J. Practical risk-based approach to assess vial's dimensions deviations effect on the aseptic filling processing according to ICH Q9 Guideline. *International Journal of Pharmacy and Pharmaceutical Sciences*. 2014; 6(9):613-616.
- 18- Mohammad Sadeq Khosravy, Mehdi Shafiee Ardestani, Reza Ahangari Cohan, **Delaram Doroud**, Safieh Amini, Seyed Bahman Momen, Seyed Mohammad Atyabi, Hossein Hedyeh, Rohalloh Vahabpour. Design, Synthesis, Physicochemical and Immunological Characterization of Dendrimer-HBsAg Conjugate
- 19- Saljoughian, N; Zahedifard, F; **Doroud, D**; Doustdari, F; Vasei, M; Papadopoulou, B; Rafati, S. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice. *Parasite immunology*. 35 (12), 397-408.
- 20- Saljoughian, N; Taheri, T; Zahedifard, F; Taslimi, Y; Doustdari, F; Bolhassani, A; **Doroud, D**; Azizi, H; Heidari, K; Vasei, M Namvar Asl, N; Papadopoulou, B; Rafati S. Development of novel prime-boost strategies based on a tri-gene fusion recombinant *L. tarentolae* vaccine against experimental murine visceral Leishmaniasis. *PLoS neglected tropical diseases*. 7 (4), e2174.
- 21- Ghadiri, M; Fatemi, S; Vatanara, A; **Doroud, D**; Rouholamini Najafabadi, A; Darabi, M; Rahimi, AA. Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size. *International journal of pharmaceutics*. 424 (1), 128-137.

- 22- **Doroud, D**; Rafati S. Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems. *Expert review of vaccines*. 11 (1), 69-86.
- 23- **Doroud, D**; Zahedifard, F; Vatanara, A; Najafabadi, AR; Taslimi, Y; Vahabpour, R; Torkashvand, F; Vaziri, B; Rafati, S. Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection. *J Control Release* 153, 1540 (2011).
- 24- Maryam Ghadiri, Alireza Vatanara, **Delaram Doroud** and A. Roholamini Najafabadi. Paromomycin loaded solid lipid nanoparticles: Characterization of production parameters. *Biotechnology and Bioprocess Engineering*. Volume 16, Number 3, 617-623, DOI: 10.1007/s12257-010-0331-5.
- 25- **Doroud, D**; Zahedifard, F; Vatanara, A; Taslimi, Y; Vahabpour, R; Torkashvand, F; Vaziri, B; Rouholamini Najafabadi, A; Rafati, S. C-terminal domain deletion enhances the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in BALB/c mice. *PLoS Negl Trop Dis* 5, 12360 (2011).
- 26- **Doroud, D**; Zahedifard, F; Vatanara, A; Najafabadi, AR; Rafati, S. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice. *Parasite Immunol.* 33, 3350 (2011).
- 27- **Doroud, D**; Vatanara, A; Zahedifard, F; Gholami, E; Vahabpour, R; Najafabadi, AR; Rafati, S. Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. *J Control Release* 148, 1050 (2010).
- 28- **Delaram Doroud**; Alireza Vatanara; Farnaz Zahedifard; Elham Gholami; Rouhollah Vahabpour; Abdolhossein Rouholamini Najafabadi; Sima Rafati. Cationic solid lipid nanoparticles loaded by cysteine proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations. *J Pharm Pharm Sci* 13, 320 (2010).
- 29- M. Mohammadi, **D. Doroud**, S. Saberi Kashani, M. Douraghi, N. Mohajerani, M. Esmaeili, M. Bababeik, A. Oghalaie, Y. Talebkhan. RAPD Patterns of Resistant and Susceptible Iranian Helicobacter pylori Strains. *International Journal of Infectious Diseases, Volume 12, Supplement 1, December 2008, Pages 110-111.*

- 30- **D. Doroud**, M. Mohammadi, N. Mohajerani, S. Massarrat. **2005**. Helicobacter pylori Antibiotic Resistance in Iran. World J Gastroenterol; 11(38):6009-6013.
- 31- M. Mohammadi, **D. Doroud**, S. Massarrat, M. Farahvash. **2003**. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; *Helicobacter*; 8(1): 80-83.

Books:

1. Co Author in: Text Book of Tuberculosis, Supervised and Coordinated By: Dr. Ali Akbar Velayati
2. Quality Control of Biopharmaceuticals. Vol: 1, Chapter: Quality by Design in the manufacturing of Biopharmaceuticals. Pages: 129-150.
3. Step by Step Guidance on cleaning validation in pharmaceutical industries. 2016 published by Sobhan publisher
4. Nanotechnology in medicine, principles and applications, 2018

Congresses Attended

-) "From Erythropoietin to Pasteupoitin", 1393/02/01, Pasteur Institute of Iran (Oral Presentation)
-)12th International Congress of Immunology & Allergy, In vitro evaluation of paromomycin formulated with Solid Lipid Nanoparticle on Leishmania major and Leishmania tropica. April 29-May 2, 2014 TEHRAN, IRAN.
-)The 13th edition of the European Symposium on Controlled Drug Delivery, in vitro evaluation of paromomycin formulated with solid lipid nanoparticle on *l. major* and *l. tropica*. April 16–18, 2014, Egmond aan Zee, The Netherlands.
-) "Internal Auditing and principles of quality management system in food and drug laboratories, medical genetics, and diagnostics", 93/09/09 to 12/09/93, Tehran, Iran (Oral Presentation)
-) 10th International Congress of Immunology & Allergy of Iran, May18-20, 2010, Tehran. Enhanced transfection efficiency toxicity ratio of a novel *Leishmania* DNA cocktail vaccine formulated with positively charged biocompatible soild lipid nanoparticles. **D. Droud**, A. Vatanara, F. Zahedifard, E. Gholami, R. Vahabpour, A. Rouholamini Najafabadi, S. Rafati. (Oral Presentation)
-) 14TH International Congress of Immunology, August 22-27,2010 Kobe, Japan
a Enhanced transfection efficiency toxicity ratio of a novel *Leishmania* DNA cocktail vaccine formulated with positively charged biocompatible soild lipid nanoparticles. **D. Droud**, A.

Vatanara, F. Zahedifard, E. Gholami, R. Vahabpour, A. Rouholamini Najafabadi, S. Rafati. (Oral Presentation)

-) 11th European symposium of control release, Netherland, April 7-9, 2010. Enhanced transfection efficiency toxicity ratio of a novel *Leishmania* DNA cocktail vaccine formulated with positively charged biocompatible solid lipid nanoparticles. **D. Droud**, A. Vatanara, F. Zahedifard, E. Gholami, R. Vahabpour, A. Rouholamini Najafabadi, S. Rafati. (Poster Presentation).

-) 10th International Congress on Immunology and Allergy, 89/2/28 to 89/2/30, Shahid Beheshti University, Tehran, Iran.

-) Paromomycin sulfate-loaded Solid Lipid Nanoparticles intended for Transdermal Delivery in cutaneous leishmaniasis (CL). **Delaram Doroud**, Maryam Ghadiri, Alireza Vatanara, Abdolhossein Rouholamini Najafabadi, Shohre Fatemi, 4th Iranian Controlled Release Conference (**ICRC2009**). (Oral presentation)

-) Quality Control of Biotechnological Vaccines, a Realistic Model from Pasteur Institute of Iran **Delaram Doroud**, .Shahriyar Omidvar , Abdolhossein Rouholamini Najafabadi, p175, The 11th Iranian Pharmaceutical Sciences Conference (IPSC2008)". (Oral presentation)

-) Quality Control of Biologics: Conventional or other Modern Analytical Techniques? Delaram Doroud, Tahereh Sadeghchah , Amir Abbas Rahimi , Mohammad Reza Jebeli , Abdolhossein Rouholamini Najafabadi , p201, The 11th Iranian Pharmaceutical Sciences Conference (IPSC2008)". (Oral presentation)

-) Maryam Ghadiri, **Delaram Doroud**, Alireza Vatanara, Alireza Vatanara, Shohreh Fatemi, Abdolhossein Rouholamini Najafabadi . "*Evaluation of Influenced Parameters on Preparation of Paromomycin-Loaded Solid Lipid Nanoparticles Using Fractional Factorial Design*" http://www.internationalaset.com/2010_nanotechnology_conference/schedule_ICNFA10.pdf. (Oral presentation).

-) The 3rd Iranian Conference of Novel Drug Delivery Systems", June 21st, 2007, Tehran University of Medical Sciences.

-) M. Mohammadi, **D. Doroud**, HP Research Group, Clinical Team, H. R. Vaziri, A. Abdi., M. Mohagheghi. Colloque Scientifique du Reseau International des Instituts Pasteur. Alger 16-17 Nov **2005**.

-) **D. Doroud**, M. Mohammadi, L. Zamaninia, M. Feizabadi, H. Colding, and L.P. Andersen. 2005. Determination of genetic diversity among Iranian and Danish strains of *Helicobacter pylori* via RAPD-PCR fingerprinting. *Helicobacter*;10 (5):468.
-) **D. Doroud**, M. Mohammadi, Y. Talebkhan, L. Zamaninia, H. R. Vaziri, M. A. Mohagheghi, M. Ghaffarpour, N. Mohajerani, and A. Nahvijoo. 2005. Determination of single versus multi-strain infection in gastric cancer versus noncancer patients by microbiologic mapping and fingerprinting of *Helicobacter pylori* via RAPD-PCR fingerprinting. *Helicobacter*;10 (5):469.
-) Oghalaie A. **D. Doroud** , HP Research Group, M. Eshagh Hosseini, G. R. Habibi, Clinical Team, M. A. Mohagheghi and M. Mohammadi. 2005. Molecular detection of host cytokine expression in cancer and non-cancer *Helicobacter pylori* patients via semi-quantitative RT-PCR. Fourth National Biotechnology Congress. P. 25.
-) Ghaffarpour M., **D. Doroud** , HP Research Group, M. A. Mohagheghi, H.R. Vaziri, Clinical Team, and M. Mohammadi. 2005. Genotyping and phenotyping *Helicobacter pylori* virulence markers in Iranian gastric cancer and non gastric cancer patients. Fourth National Biotechnology Congress. P. 28.
-) **Doroud D.**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Determination of single vs. multi-strain infection in gastric cancer vs. non-cancer patients by microbiologic mapping and finger printing. Fourth National Biotechnology Congress. P. 24.
-) Zohari M., **D. Doroud** HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Association between pro-inflammatory cytokine gene polymorphism and increased risk of gastric cancer. Fourth National Biotechnology Congress. P. 27.
-) **Doroud, D.**, N. Mohajerani, S. Massarrat, and M. Mohammadi. 2005. Are molecular methods appropriate substitutions for traditional antimicrobial assays in detecting *Helicobacter pylori* antibiotic resistance in Iranian clinical trials? Fourth National Biotechnology Congress. P. 303.
-) Oghalaie, **D. Doroud** , HP Research Group, Clinical Team, M. Eshagh Hosseini, M. A. Mohagheghi and M. Mohammadi. 2005. Cytokine gene expression in gastric cancer patients via semi-quantitative RT-PCR. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 70.

-) 3rd Regional Conference (Asia-Pacific) on Cancer Prevention (Gastrointestinal cancer Prevention), Ordibehesht, 5-7th, 1384, Guilan, Iran.
-) M. Ghaffarpour, **D. Doroud** , HP Research Group, Clinical Team, M. H. R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Evaluation of Host Response toward Helicobacter pylori antigens in gastric adenocarcinoma patients; Significance of anti-CagA and VacA antibodies. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 59-60. 7
-) Y. Talebkhan, N. Mohajerani, **D. Doroud** , HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Risk factors in the pathogenesis of gastric cancer among Iranian population. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 76-77.
-) **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. 2005. Determination of single vs. multi-strain infection in gastric cancer vs. non-cancer patients by microbiologic mapping and finger printing. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 141-142.
-) Y. Talebkhan, **D. Doroud** , HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Is pepsinogen I a reliable marker for prognosis of gastric cancer among Iranian population. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 178.
-) Y. Talebkhan, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Detection of predominant Helicobacter pylori genotypes among Iranian gastric cancer and non gastric cancer patients. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 179-180.
-) L. Zamaninia, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and M. Mohammadi. 2005. Pattern of Helicobacter pylori colonization in the gastric epithelium of gastric cancer and non cancer patients. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 186-187.
-) M. Zohari, **D. Doroud**, HP Research Group, Clinical Team, H.R. Vaziri, M. A. Mohagheghi and **M. Mohammadi**. 2005. Association between pro-inflammatory cytokine gene polymorphism

and increased risk of gastric cancer. Third Regional Conference of Asian Pacific Organization for Cancer Prevention (APOCP) GI Cancer Control. P. 188-189.

-) M. Mohammadi, **Delaram Doroud**, Nazanin Mohajerani, Leili Zamaninia, and Leif Percival Andersen. **2004**. Correlation of the rdxA gene deletion and metronidazole resistance in Iranian *Helicobacter pylori* strains. Sixth International conference on pathogenesis and host response in Helicobacter infection. Helsingor, Denmark. *Oral presentation*. P:31

-) M. Mohammadi, **D. Doroud**, N. Mohajerani, A. Oghalaie, S. Massarrat, M. Farahvash. **2003**. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; Is it a Drug of Choice for Iran? *Helicobacter*; 8(4):471.

-) M. Mohammadi, **D. Doroud**, L. Zamaninia, S. Massarrat, H. Colding, L. P. Andersen. **2003**. Molecular analysis of *Helicobacter pylori* using RAPD-PCR fingerprinting to determine genetic diversity between Iranian and Danish strains. *Helicobacter*;8(4):396.

-) **D. Doroud**, N. Mohajerani, A. Oghalaie, S. Massarrat, M. Farahvash, M. Mohammadi. 2003. Clarithromycin Resistance in Iranian *Helicobacter pylori* Strains; Is it a Drug of Choice for Iran? *International Journal of Medical Microbiology*. 293 (35): 38-41.

-) **D. Doroud**, L. Zamaninia, S. Massarrat, H. Colding, L. P. Andersen, M. Mohammadi. 2003. Molecular analysis of *Helicobacter pylori* using RAPDPCR fingerprinting to determine genetic diversity between Iranian and Danish strains. *International Journal of Medical Microbiology*. 293 (35): 96

-) **D. Doroud** and M. Mohammadi. **2001**. Molecular detection of antibiotic resistance in *Helicobacter pylori*. *Proceedings of Second International Biotechnology Congress*. 2: 1067-1073

-) Mohammadi M. **D. Doroud**, N. Mohajerani, A. Oghalaie, H. Colding and L. P. Andersen. **2001**. Enzymatic Digestion profiles of the *Helicobacter pylori* cytotoxin and its association with peptic ulcer disease. *International Journal of Medical Microbiology*. 291 (31): 33

Workshops Attended

-) “Quality Control & Basic Statistics”, March 5th,2014, Tehran, Iran.

-) Principles of Inspection of Quality Control Laboratories in Pharmaceutical Industry according to WHO and PIC/S Guidelines”, 93/07/15 to 93/07/16, Tehran, Iran.
-) “Preparation of Working Standards”, Held on 18th-20th December 2012, Tehran, Iran.
-) “Basic and Internal Assessment in Accordance with EN ISO/IEC 17025:2005”, Held on 5th-6th October 2011, Tehran, Iran.
-) ”Synthesis, Production, Characterization, and Applications of Nano-sized Materials”, Held on May 2009, The 2nd Iran-India Conference on Nanotechnology.
-) International Workshop on *Leishmania*, March 1-6th, 2008. Pasteur Institute of Iran.
-) “New Achievements in Biomedical Engineering & Artificial Organs”, October 4th, 2008, Tehran, Iran.
-) “New Frontiers in Biotechnology”, October 4th, 2008, Tehran, Iran.
-) “Biological-pharmaceutical Preparations”, Held on June 21st, 2007. Iran.
-) “Research Methods in Pharmaceutical Sciences”, Held on Autumn 2007, Tehran, Iran.
-) “An Introduction to the Planning for Project Management”, February 14th, 2006.
-) “Documentation Basics for Good Manufacturing Practice”, Held on August 2nd, 2006, Tehran, Iran.
-) “Introduction to ISO/IEC 17025:2005”, Held on April 17th 2006, Behbood Fara Pouya Co. Tehran, Iran.
-) “Sampling”, January, 29th, 2006, Pasteur Institute of Iran.
-) Workshop on “Lot Release/ Lab Access”, August 22-25th, 2005, Tehran, Iran.

Dissertations Advised

1. Consulting a PhD Dissertation (Mehdi Shahbazi) titled “Evaluation of Immunogenicity and protective role of *Leishmania tarentole* incorporated with cystein Protease genes and A2 genes against *Leishmania Infantum* Infection as a new method for vaccine production in canine models” for Isfahan University of medical Sciences. 2011-2015
2. Consulting a PhD Dissertation (*Maryam Heidari* Kharaji) titled “In vitro evaluation of solid lipid Nanoparticle harboring paramomycin on *Leishmania major* and *L. tropica* and its treatment efficacy on *L. major* infected BALB/c mice ” for Pasteur institute of Iran. 2011-up to present.

3. Advising a PhD Dissertation (Mohsen Mehrabi) titled “synthesis and Evaluation of Immunogenicity and protection of *chitosan nanoparticles* incorporated with hbsAg as a new adjuvant system for hepatitis b vaccine delivery in murin model” for Tehran university of medical sciences. 2013-present.
4. Advising a Msc Dissertation (Shabnam Gholinejad) titled “Real Time stability and optimization of the albumin-free recombinant streptokinase formulation” for Damghan university of medical sciences. 2013-2014
5. Advising a Msc Dissertation (Fatemeh khalilinia) titled “Formulation, Real Time Stability and Viability Studies of the Lyophilized *Leishmania* parasite ” for Damghan university of medical sciences. 2013-2015.
6. Advising a Pharm D Dissertation (Zahra Anbaee Farimani) titled “Cleaning validation for residual estimation of recombinant insuline on formulaion and filling equipments of a biopharmaceutical manufacturing line” for Azad university of pharmaceutical sciences.2015-present.
7. Advising a Pharm D Dissertation (Ashkan Shahabi Miyankooh) titled Preparation and evaluation of a topical formulation containing SLN loaded Paramomycin for cutaneous Leishmaniasis
8. Advising a Ph D Dissertation (Hediyeh Rassam) titled Preparation and evaluation of the recombinant streptokinase loaded solid lipid nanoparticle
9. Advising a Msc Dissertation (Maryam Mostafa nejad) titled Preparation and evaluation of a SLN loaded Paramomycin intended to be used as an antimicrobial agent
10. Advertising a Msc Dissertation (Marjan Khatami) titled Evaluation of the Biological Activity of Solid Lipid Nanoparticles Loaded Interferon α -2b: an In Vitro Study
11. Advising a Pharm D Dissertation (Haleh Moini) titled Preparation and evaluation of the physicochemical characterization of the solid lipid nanoparticles harbouring rHBsAg as vaccine candidate
12. Advising a Pharm D Dissertation (Hossein Aghajani alishah) Preparation and evaluaton of the cell culture and competence of the manosilated solid lipid nanoparticles harbouring r HBs Ag as vaccine candidate in *in-vitro* conditions

